Legend Biotech (LEGN) Expected to Announce Earnings on Tuesday

Legend Biotech (NASDAQ:LEGN) will likely be announcing its earnings results before the market opens on Tuesday, March 11th. Analysts expect the company to announce earnings of ($0.34) per share and revenue of $179.00 million for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Legend Biotech Stock Down 5.8 %

Shares of Legend Biotech stock opened at $32.98 on Tuesday. The company has a current ratio of 4.98, a quick ratio of 4.90 and a debt-to-equity ratio of 0.27. The company’s fifty day simple moving average is $35.21 and its two-hundred day simple moving average is $42.08. The company has a market cap of $6.02 billion, a P/E ratio of -34.72 and a beta of 0.18. Legend Biotech has a 12-month low of $30.17 and a 12-month high of $69.24.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on LEGN shares. Royal Bank of Canada reissued an “outperform” rating and set a $86.00 price objective on shares of Legend Biotech in a research report on Monday, December 9th. HC Wainwright reaffirmed a “buy” rating and issued a $73.00 target price on shares of Legend Biotech in a research report on Tuesday, January 21st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $83.00 target price on shares of Legend Biotech in a research report on Monday, December 9th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $78.00 target price on shares of Legend Biotech in a research report on Monday, December 30th. Twelve analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $79.50.

Legend Biotech Company Profile

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM).